AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...
Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss and liver health benefits.
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand ...
Zacks.com on MSN2d
RHHBY Enters Into a $5.3B Deal With Zealand Pharma for Obesity DrugRoche RHHBY announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma for an ...
Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma.
Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...
Vietnam Investment Review on MSN3d
Ascletis Announces Positive Topline Results of Phase Ib Studies of ASC47 Monotherapy in Australia and U S FDA Clearance of IND Application for ASC47 in Combination with SemaglutideASC47, an adipose-targeted muscle-preserving weight loss drug candidate for the treatment of obesity, demonstrated a half-life of up to 26 days and 40 days, respectively, in Phase Ib single ...
Clinical Trials Arena on MSN2d
Ascletis’ muscle-preserving weight loss therapy sustains 40-day half-lifeThe company’s weight loss therapy was able to sustain itself for up to 40 days in obese patients after a single injection.
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback